Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

ABSTRACT:

Background

Response to first-line treatment in acute graft-versus-host disease (GVHD) is typically assessed at day 28 (D28) in clinical trials, but this convention was established without accounting for onset severity and thus was optimized for mild-moderate GVHD that comprises the majority of cases. Furthermore, the initiation of second-line therapy, which is considered primary treatment failure, is not based on standardized criteria and thus remains subjective and inconsistent for patients regardless of clinical trial participation.

Objective

In this study we hypothesized that an early assessment of treatment response at D7 would accurately predict long-term outcomes for patients with severe GVHD and support the initiation of second line therapy in non-responders.

Study

SUBMITTER: Louloudis IE 

PROVIDER: S-EPMC12636002 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature